Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 16/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2070607 | 0.85 | CRHR1 (0.65) | CRHR1KDM4E | |
| SCHEMBL2069225 | 0.81 | CRHR1 (0.80) | CRHR1 | |
| SCHEMBL2072415 | 0.81 | CRHR1 (0.55) | CRHR1TSHR | |
| SCHEMBL2070441 | 0.81 | CRHR1 (0.54) | CRHR1 | |
| SCHEMBL2072641 | 0.76 | CRHR1 (0.66) | CRHR1TSHRALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL2071954 | 0.75 | CRHR1 (1.00) | CRHR1 | |
| SCHEMBL2072133 | 0.73 | CRHR1 (0.51) | CRHR1CYP1A2 | |
| SCHEMBL2071597 | 0.73 | CRHR1 (1.00) | CRHR1 | |
| SCHEMBL2070099 | 0.73 | CRHR1 (0.62) | CRHR1ALDH1A1 | |
| SCHEMBL2071874 | 0.72 | CRHR1 (0.76) | CRHR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2522670-A1 | Heterocyclic CRF receptor antagonists | Takeda Pharmaceutical Company Limited (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-7897607-B2 | Cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-01 | — | — | US | disclosed |
| US-20070179165-A1 | Cyclic compounds | GYORKOS ALBERT C | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179165-A1 | Cyclic compounds | CRHR1, CRHR2, MC2R | CRHR1 1/4885TSHR 311/4885KDM4E 3537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.